Catalog No.
DHC12516
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG
Clonality
Monoclonal
Target
AICD-57, A4, Beta-CTF, Protease nexin-II, Gamma-CTF(50), ABPP, S-APP-beta, APP, Abeta40, Abeta42, AID(59), Amyloid intracellular domain 59, AID(57), S-APP-alpha, Gamma-CTF(59), Beta-secretase C-terminal fragment, Amyloid-beta precursor protein, Amyloid precursor protein, Beta-APP42, PreA4, Alzheimer disease amyloid protein, APPI, PN-II, AICD-59, Alpha-secretase C-terminal fragment, Amyloid-beta A4 protein, Amyloid intracellular domain 57, CVAP, Amyloid intracellular domain 50, Beta-APP40, AD1, Cerebral vascular amyloid peptide, AID(50), Alpha-CTF, Gamma-CTF(57), AICD-50
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P05067
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
BI-1034020, BI 1034020, BI1034020
Clone ID
BI 1034020
Monitoring of amyloid related imaging abnormalities: SWI vs T2*-GRE., PMID:40537339
TNFR2 contributes to synaptic potentiation failure in hippocampal synapses and memory loss in a familial Alzheimer's disease mouse model., PMID:40527437
Cargo of small extracellular vesicles from neuronal origin shows progression of dementia in individuals with Down syndrome., PMID:40524460
Preclinical Evidence of Withania somnifera and Cordyceps spp.: Neuroprotective Properties for the Management of Alzheimer's Disease., PMID:40508211
Lecanemab Binds to Transgenic Mouse Model-Derived Amyloid-β Fibril Structures Resembling Alzheimer's Disease Type I, Type II and Arctic Folds., PMID:40495448
β-Amyloid as a new target to suppress tonic PTH hypersecretion in primary hyperparathyroidism., PMID:40492090
Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application., PMID:40486952
[Morphomolecular subtyping of hepatocellular adenoma]., PMID:40471284
Protocol for culture, purification, and target validation of a hybridoma-generated monoclonal antibody targeting Aβ truncated species., PMID:40465455
Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease., PMID:40459787
Anti-pyroglutamate-3 Aβ immunotherapy engages microglia and inhibits amyloid accumulation in transgenic mouse models of Aβ amyloidosis., PMID:40455292
Intracellular and Extracellular Localization of Transthyretin and Its Association With Amyloid-β in Alzheimer's Disease Brains., PMID:40448526
Hippocampal subfields: volume, neuropathological vulnerability and cognitive decline in Alzheimer's and Parkinson's disease., PMID:40448161
Chimeric antigen receptors discriminate between tau and distinct amyloid-beta species., PMID:40448101
Proteomic signatures of corona and herpes viral antibodies identify IGDCC4 as a mediator of neurodegeneration., PMID:40446030
The impact of autoimmune thyroid disease on cognitive and psychiatric disorders: focus on clinical, pre-clinical and molecular studies., PMID:40445744
Acute targeting of N-terminal tau protein has long-lasting beneficial effects in Tg2576 APP/Aβ mouse model by reducing cognitive impairment, cerebral Aβ-amyloidosis, synaptic remodeling and microgliosis later in life., PMID:40442822
Lecanemab in clinical practice: real-world outcomes in early Alzheimer's disease., PMID:40437535
The distinct effect between Amyloid β (1‒40) and Amyloid β (1‒42) on the TRAP-stimulated platelet activation in diabetes mellitus., PMID:40436763
Nanoimmunomodulation of the Aβ-STING feedback machinery in microglia for Alzheimer's disease treatment., PMID:40434641
PET imaging of TREM2 in amyloid-beta induced neuroinflammation., PMID:40434494
Engagement of CD300c by a Novel Monoclonal Antibody Ameliorates Behavioral Deficits in a 5xFAD Mouse Model of Alzheimer's Disease., PMID:40426995
Bispecific brain-penetrant antibodies for treatment of Alzheimer's disease., PMID:40425446
Nanoplatforms Targeting Intrinsically Disordered Protein Aggregation for Translational Neuroscience Applications., PMID:40423094
[Prospects for treating Alzheimer's disease]., PMID:40420451
Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer's disease., PMID:40417267
The NLRP3-P2X7 Axis and Cytokine Crosstalk in Alzheimer's Disease: Mechanisms, Implications, and Therapeutic Opportunities., PMID:40415299
Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC., PMID:40413561
Lower baseline amyloid beta burden is associated with greater percent of amyloid beta positron emission tomography reduction and better clinical outcomes in the aducanumab Phase 3 trials ENGAGE and EMERGE in early Alzheimer's disease., PMID:40413110
Discovery of an APP-selective BACE1 inhibitor for Alzheimer's disease., PMID:40399225
Association of neurobiological and immune serum biomarkers with Toxoplasma gondii infection in patients with schizophrenia., PMID:40397143
Co-occurrence of Down Syndrome and Multiple Sclerosis., PMID:40395918
Anti-Amyloid Agents: A Self-Fulfilling prophecy., PMID:40393205
Fluid biomarkers in atypical Parkinsonism: current state and future perspectives., PMID:40392273
Impact of Manganese on Neuronal Function: An Exploratory MultiOmic Study on Ferroalloy Workers in Brescia, Italy., PMID:40385409
Safety, Tolerability, and Pharmacokinetics of Donanemab in Healthy Chinese Participants: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study., PMID:40377397
Direct and selective nanosensor for amyloid-β oligomers in serum for Alzheimer's disease diagnosis., PMID:40376667
Antibodies target different amyloid-β species., PMID:40374957
Clinical evaluation of medicines for patients with mild cognitive impairment and mild dementia due to Alzheimer's disease in Japan., PMID:40370495
Juxtacortical Lesion Precedes Lobar Microbleed During Anti-amyloid β Immunotherapy., PMID:40368787
Supramolecular Copolymerization of Glycopeptide Amphiphiles and Amyloid Peptides Improves Neuron Survival., PMID:40365999
Alzheimer's Is a Multiform Disease of Sustained Neuronal Integrated Stress Response Driven by the C99 Fragment Generated Independently of AβPP; Proteolytic Production of Aβ Is Suppressed in AD-Affected Neurons: Evolution of a Theory., PMID:40362488
Standardization of criteria in MacCAT-T and MacCAT-CR for monoclonal anti-beta-amyloid antibodies: A Delphi study., PMID:40357142
High precision and cost-effective multiplex quantification of amyloid-β40, amyloid-β42, p181Tau, p217Tau, neurofilament light chain, and glial fibrillary acidic protein from plasma and serum., PMID:40356374
Structural and biochemical differences between non-catalytic and catalytic antibodies., PMID:40356286
Lecanemab Treatment in a Specialty Memory Clinic., PMID:40354064
[An Update on Hereditary Dementias]., PMID:40350628
Inactivation of SIAH-1 E3 ligase attenuates Aβ toxicity by suppressing ubiquitin-dependent DVE-1 degradation in Caenorhabditis elegans models of Alzheimer's disease., PMID:40349774
The Efficacy of Anti-amyloid Monoclonal Antibodies in Early Alzheimer's Dementia: A Systematic Review., PMID:40346804
Identifying suppressive factors of Alzheimer's disease through comprehensive analysis of real-world data: a single-center retrospective study., PMID:40346511
For research use only. Not for human or drug use.
